Biotech Values

[biocqr]

NVAX - positive results on avian flu vaccine.

Novavax soars on avian flu vaccine
Thursday August 25, 1:02 pm ET

Stock in Novavax jumped as much as 41 percent Thursday after the company reported positive results from an experimental vaccine for avian influenza.
Novavax, which moved its headquarters from Columbia to the Philadelphia area in September, still has a research laboratory in Rockville.

The company reported in the journal Vaccine that an avian flu vaccine developed with its proprietary technology protected animals from the virus in preclinical trials.

Virus-Like Particle technology, or VLP, is an alternative to traditional methods of producing vaccines. The technology is capable of producing large quantities of vaccine in a short period, Novavax says.

The company's stock (NASDAQ: NVAX - News) was up 25 cents to $1.21 per share in Thursday trading on volume of more than 8 million shares, 16 times its normal trading volume.

Novavax also develops hormone replacement therapies and prescription prenatal vitamins.

It lost $5.7 million last quarter, compared with a $7.7 million net loss in the same quarter a year ago.

Published August 25, 2005 by the Washington Business Journal


http://biz.yahoo.com/bizj/050825/1155907.html?.v=1